JCNRJournal of Clinical and Nursing Research2208-36852208-3693Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcnr.v8i4.6772ArticleObservation on the Clinical Effect of Applying Vinaclat Combined with Demethylation Drug Therapy in Patients with Acute Myeloid Leukemiahttps://artdesignp.com/journal/JCNR/8/4/10.26689/jcnr.v8i4.6772NiuBen,HouLimin2024842024-04-30Objective: To investigate the therapeutic effect of applying venetoclax combined with demethylating drugs in treating patients with acute myeloid leukemia (AML). Methods: Eighty cases of AML patients treated with venetoclax combined with demethylating drugs in our hospital were selected from March 2021 to March 2024, including 40 cases of primary treatment patients and 40 cases of relapsed and refractory patients. The efficacy and safety of the combined drug therapy was analyzed. Results: The primary treatment group was presented with a complete remission (CR) rate of 40.5%, partial remission (PR) rate of 47.50%, no response (NR) rate of 12.50%, and a remission rate of 87.50%. The relapsed- refractory group was presented with a CR rate of 37.50%, PR rate of 42.50%, NR rate of 17.50%, and a remission rate of 87.50%. There was no statistical significance between the groups (P > 0.05). The hematological adverse reactions of the combined treatment for AML were leukopenia and the non-hematological adverse reactions were mainly infections, with an incidence rate of 87.50%. Conclusion: The efficacy of venetoclax combined with demethylating drugs in AML was remarkable and the treatment regimen can be adjusted according to the treatment-resistant response.

Wang Y, Huang S, Zhang X, et al., 2023, Clinical Observation of Venetoclax Combined with Demethylating Agents on the Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Chinese Journal of Experimental Hematology, 31(2): 327–332.

Yan L, Wang W, Dong X, et al., 2023, Clinical study of Venetoclax combined with demethylating drugs in the treatment of acute myeloid leukemia[J]. China Cancer Clinics, 50(12): 636–642.

Qian J, Huang H, Wang X, et al., 2022, Efficacy and Safety Of Venetoclax Combined with Demethylating Drugs in The Treatment of 42 Cases of Elderly Acute Myeloid Leukemia. China Clinical Research, 36(3): 415–420.

Yan C, Wang X, Yang L, et al., 2022, Observation on the Effect of Bcl-2 Inhibitor Venetoclax Combined with Demethylating Drugs in Treating 8 Cases of Elderly Acute Myeloid Leukemia. Transportation Medicine, 36(5): 515– 516.

Feng J, Yuan R, Tang H, et al., 2023, Analysis on the Efficacy and Safety of Venetoclax in the Treatment of Acute Myeloid Leukemia. Chinese Journal of Experimental Hematology, 31(4): 960–966.

Zhang J, Song B, Kong X, et al., 2023, Analysis of the Efficacy of Celinisol Combined with Demethylating Drugs in The Treatment of Vinblastine-Exposed Refractory/Relapsed Acute Myeloid Leukemia. Chinese Journal of Hematology, 44(11): 936–939.

Fan C, Yan L, Wang X, et al., 2022, A Case Analysis of a Combination of Venetoclax in The Treatment of Acute Myeloid Leukemia in The Elderly. Chinese Journal of Clinical Pharmacy, 31(5): 392–394.

Yang L, Wang S, Hu W, et al., 2022, Clinical Efficacy Analysis of Azacitidine Combined with Venetoclax in The Treatment of Elderly Patients with Acute Myeloid Leukemia. Journal of Clinical Hematology, 35(7): 512–516 + 521.

Luo D, Yu J, Li X, et al., 2022, Efficacy and Safety of Induction Therapy in First-Treatment Elderly Patients with Acute Myeloid Leukemia Intolerant to Intensive Chemotherapy. Internal Medicine Theory and Practice, 17(3): 220– 226.

Fu L, Liao X, Xiong M, 2022, Efficacy of Venetoclax Combined with Azacitidine in the Treatment of Acute Myeloid Leukemia in The Elderly and Its Effect on Patients’ Immune Function. Geriatrics and Health Care, 28(1): 125–128 + 134.